Ironwood Pharmaceuticals is a gastrointestinal-focused company best known for linaclotide, marketed as Linzess in the U.S. for irritable bowel syndrome with constipation and chronic idiopathic constipation. The product is commercialized with partners and remains the core of its specialty GI franchise. Ironwood also advances additional GI and related pipeline candidates aimed at disorders with substantial unmet need. Its strategy centers on specialty gastroenterology rather than broad primary-care portfolios.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 85.2 | — | 23.6 | — |
| Q3 2025 | 122.1 | — | 40.1 | 1,154.5% |
| Q4 2025 | 47.7 | — | -2.3 | -171.1% |
| Q1 2026 | 106.5 | — | 40.8 | — |
| Q2 2026 | 113 | 32.6% | 51.3 | 117.3% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Real REMAX Group Inc. (REAX), The Elmet Group Co. (ELMT), Olema Pharmaceuticals, Inc. (OLMA), Churchill Capital Corp XII (CXII), Bridgewater Bancshares, Inc. (BWB), OrthoPediatrics Corp. (KIDS)